New cancer drug combo tested in early trial, but study halted

NCT ID NCT06560632

Terminated Disease control Sponsor: Repare Therapeutics Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times

Summary

This early-phase trial tested a new drug called RP-3467, alone or combined with olaparib, in 26 adults with advanced solid tumors that had stopped responding to other treatments. The main goal was to check safety and find the right dose. The study was terminated early, so results are limited.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

# 1001, The University of Texas M.D. Anderson Cancer Center

Houston, Texas, 77030, United States
# 1004, Memorial Sloan-Kettering Cancer Center

New York, New York, 10065, United States
# 1008, Columbia University

New York, New York, 10032, United States
# 1011, The Washington University

St Louis, Missouri, 63130, United States
# 1025, The University of California

San Francisco, California, 94158, United States

Conditions

Explore the condition pages connected to this study.

ADVANCED SOLID TUMOR